Literature DB >> 10456407

Reoperations for acute prosthetic thrombosis and pannus: an assessment of rates, relationship and risk.

G Rizzoli1, C Guglielmi, G Toscano, V Pistorio, I Vendramin, T Bottio, G Thiene, D Casarotto.   

Abstract

OBJECTIVE: Mechanical valvular prostheses have the advantage of longevity but carry a risk of thrombosis which is dependant on valve design, materials and host-related interface. While pannus is common to both biologic and mechanical valves, acute prosthetic thrombosis is mostly a complication of mechanical valves; therefore we investigated to find rates and risk of these obstructive complications.
METHODS: Between 1/1/70 and 31/12/97, 2680 patients received at least one mechanical prosthesis in the aortic or mitral or tricuspid position and a total of 3014 operations were performed. Follow-up included 18523 years and was 98% complete. Incidence rates, Kaplan-Meier estimates, modeling of the hazard and multivariate analysis in the hazard domain were used in the analysis.
RESULTS: Overall survival was 76%, 64%, 51%, 38.5% and 29% at 5, 10, 15, 20 and 25 years, respectively. It was significantly better in aortic than in mitral than in double prosthesis. 290 patients received a single reoperation, 37 a second, six a third and one a fourth reoperation. Two-hundred and fifty-one of these reoperations were exclusively due to malfunction of mechanical prosthesis, nine to malfunction of both mechanic and biologic prostheses. Most frequent reoperative indications was dehiscence (133), pannus (48) and thrombosis (29). The linearized rate of reoperations for pannus was 0.24%/patient per year, for valvular thrombosis 0.15%/patient per year. The shape of the thrombotic hazard was constant (at random) and the relative risk 12 times higher for tricuspid prosthesis, seven times higher for mitral prosthesis. Multivariate analysis controlling for prosthetic position, age, sex and prosthetic size, showed a 67% risk reduction with larger prosthesis (>27 mm), a 69% risk reduction with the Sorin tilting disk prosthesis and an 83% risk reduction with the bileaflet prosthesis. Pannus hazard shows a delayed exponential rise and was two times higher in tricuspid and three times higher in mitral position. Multivariate analysis showed a 50% risk reduction with larger prosthesis, an 11 times higher hazard of old (caged-disk, caged ball) prosthesis and a three times higher hazard of Lillehei-Kaster prosthesis. Reoperation for thrombosis has a 62% perioperative (30 days) survival compared to 92% survival of pannus reoperation.
CONCLUSIONS: Mechanical valves have a low incidence of reoperation, mostly for prosthetic dehiscence. Pannus development is the next frequent complication increasing with time since implant, therefore in this series it was related to old valvular models and tilting disk prosthesis, with longer follow-up. Acute thrombosis occurs significantly earlier than pannus formation. Despite shorter follow-up we are therefore confident that bileaflet prostheses are less prone to this complication and pannus is a rare early etiologic factor. Thrombosis has very high operative risk as compared to pannus, justifying the present trend to thrombolysate selected cases.

Entities:  

Mesh:

Year:  1999        PMID: 10456407     DOI: 10.1016/s1010-7940(99)00124-4

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  23 in total

1.  Dysfunction of mechanical heart valve prosthesis: experience with surgical management in 48 patients.

Authors:  Wei-Guo Ma; Bin Hou; Adiljan Abdurusul; Ding-Xu Gong; Yue Tang; Qian Chang; Jian-Ping Xu; Han-Song Sun
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

2.  Reoperation for a patient with Starr-Edwards aortic valve malfunction due to pannus formation twenty-nine years after implantation.

Authors:  Takahisa Okano; Matthew D Horton; Gary G Fermanis; David A Horton
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2005-08

Review 3.  Thrombolysis as first choice therapy in prosthetic heart valve thrombosis. A study of 68 patients.

Authors:  Fidel Manuel Cáceres-Lóriga; Horacio Pérez-López; Karel Morlans-Hernández; Humberto Facundo-Sánchez; José Santos-Gracia; Juan Valiente-Mustelier; Felipe Rodiles-Aldana; Maria Acelia Marrero-Mirayaga; Blas Y Betancourt; Pedro López-Saura
Journal:  J Thromb Thrombolysis       Date:  2006-04       Impact factor: 2.300

4.  A single center's experience with the Ross procedure in pediatrics.

Authors:  Edward Kirkpatrick; Roger Hurwitz; John Brown
Journal:  Pediatr Cardiol       Date:  2008-04-10       Impact factor: 1.655

5.  Rapid pannus formation after few months of obstructing aortic mechanical prosthesis.

Authors:  Bassel Al-Alao; Urszula Simoniuk; Brian Heron; Haralabos Parissis
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-09-25

6.  Limitations of multimodality imaging in the diagnosis of pannus formation in prosthetic aortic valve and review of the literature.

Authors:  Juan Bautista Soumoulou; Tomás Francisco Cianciulli; Andrea Zappi; Alberto Cozzarin; María Cristina Saccheri; Jorge Alberto Lax; Robert Guidoin; Ze Zhang
Journal:  World J Cardiol       Date:  2015-04-26

7.  Aorta-atria-septum combined incision for aortic valve re-replacement.

Authors:  Yiwei Xu; Xiaofeng Ye; Zhaolong Li; Qiang Zhao
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

8.  Recurrent infarctions due to a dome-shaped pannus above the mitral valve prosthesis.

Authors:  Hirofumi Kasahara; Yoshito Inoue; Satoru Suzuki
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

9.  Mitral valve-sparing procedures and prosthetic heart valve failure: a case report.

Authors:  N A Khan; J Butany; S W Leong; V Rao; R J Cusimano; H J Ross
Journal:  Can J Cardiol       Date:  2009-03       Impact factor: 5.223

Review 10.  Mechanical valve obstruction: Review of diagnostic and treatment strategies.

Authors:  Jason Salamon; Jerson Munoz-Mendoza; Jared J Liebelt; Cynthia C Taub
Journal:  World J Cardiol       Date:  2015-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.